Glerup M, et al. - From 1997 to 2000, from specified geographic areas in Denmark, Norway, Sweden, and Finland, researchers assessed the long-term progression, reduction rate and disease burden in juvenile idiopathic arthritis (JIA) 18 years after disease attack. They noticed 46% of total individuals with active disease. About 15% of cases were treated with synthetic disease-modifying antirheumatic drugs plus 84 candidates with biologics. They observed inactive disease shown by juvenile arthritis disease activity (JADAS71) <1 in 48% of participants. Overall, they concluded a high burden of disease in adulthood for JIA.